Comparing clinical outcomes of ARB and ACEi in patients hospitalized for acute COVID-19
Description
Continued receipt of Renin-Angiotensin-Aldosterone inhibitors in patients with COVID-19 has shown potential in producing better clinical outcomes. However, superiority between ACEi (angiotensin-converting enzyme inhibitors) and ARB (angiotensin II
